In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Factors that influence Heart Failure treatment titration in a Heart Failure Unit

Session Poster Session 3

Speaker Assistant Professor Gonzalo Luis Alonso Salinas

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Pharmacotherapy
  • Session type : Poster Session

Authors : GL Alonso Salinas (Madrid,ES), E Gonzalez Ferrer (Madrid,ES), S Del Prado Diaz (Madrid,ES), M Castillo Orive (Madrid,ES), S Fernandez Santos (Madrid,ES), I Rayo Llerena (Madrid,ES), M Abellas Sequeiros (Madrid,ES), JD Sanchez Vega (Madrid,ES), JM Vieitez Florez (Madrid,ES), M Pascual Izco (Madrid,ES), JL Zamorano (Madrid,ES)

Authors:
GL Alonso Salinas1 , E Gonzalez Ferrer1 , S Del Prado Diaz1 , M Castillo Orive1 , S Fernandez Santos1 , I Rayo Llerena1 , M Abellas Sequeiros1 , JD Sanchez Vega1 , JM Vieitez Florez1 , M Pascual Izco1 , JL Zamorano1 , 1Hospital Universitario Ramón y Cajal, Cardiology - Madrid - Spain ,

Citation:

Background

Heart Failure (HF) treatment titration remain one of HF Units (HFU) main problems as showed in national and European latest registries. This study aims to identify the factors that lead to an unsuccessful treatment titration.

Methods and Results

Patients seen in a HFU were consecutively included in a prospective registry from November ´18 to January ´19. Clinical, echocardiographic, analytic and treatment data were recorded.

A total of 114 patients were consecutively included. Mean age was 71.6±12.8 years, 26 (22.8%) patients were female, 19 (16.7%) were frail and 24 (42.1%) had Chronic Kidney Disease (CKD) (GFR < 60ml/min/1.73m2).

Table 1 shows treatment titration differentiation according age = 75-years (elderly population), female sex, frailty and CKD among depressed LVEF patients.

Conclusions

Age, female sex, frailty and CKD constitute factors that may influence HF treatment titration. Larger and longer studies should confirm these data

Elderly Population (n=19)

Non-Elderly Population (n=38)

P

MRA use

12, 63.2%

32, 84.2%

0.074

BB titration at target dose

7, 41.2%

17, 48.6%

0.616

IECA/ARAII/ARNI titration at target dose

3, 17.7%

18, 51.4%

0.020

Female Sex (n=11)

Male Sex (n=46)

P

MRA use

6, 54.6%

38, 82.6%

0.046

BB titration at target dose

2, 22.2%

22, 51.2%

0.113

IECA/ARAII/ARNI titration at target dose

2, 22.2%

19, 44.2%

0.222

Frail Population (n=8)

Non-Frail Population (n=49)

P

MRA use

6, 75%

38, 77.6%

0.873

BB titration at target dose

4, 57.1%

20, 44.4%

0.531

IECA/ARAII/ARNI titration at target dose

1, 14.3%

20, 44.4%

0.130

CKD Population (n=24)

Non-CKD Population (n=33)

P

MRA use

15, 62.5%

29, 87.9%

0.024

BB titration at target dose

8, 36.4%

16, 53.3%

0.225

IECA/ARAII/ARNI titration at target dose

5, 22.7%

16, 53.3%

0.026

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are